GlobeNewswire All Public CompaniesCodex · 实盘不做把握 8/10不做原因:无增量信息🔁 +1 同一事件
北京时间·🕒 发布 19:00:00·⟳ 抓取 19:00:40·⚡ 决策 08-31 19:04:04 +3m24s·57.1 天前
Beam Therapeutics宣布参加9月多场投资者会议
事件是例行参会通知，不包含会改变收入、管线成功率、监管状态、资本结构或商业化预期的新增事实，无法形成正期望交易。
📄 原文GlobeNewswire All Public Companies↗ 原文
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company deve…
不做 Beam Therapeutics Inc.（BEAM.US）
例行投资者会议公告，无临床、监管、合作、财务或指引增量，方向和edge不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Beam Therapeutics本次公告只是管理层参加三场9月投资者会议及直播安排；正文没有披露新临床结果、监管节点、合作交易、融资、业绩指引或其它可交易增量，因此即使标的可交易，也缺少方向和materiality。
🔎 新鲜度:最早出现 2026-08-31 · 扩散 low · price-in 风险 low ↗
主要风险
- 会议期间可能另有未预告信息或管理层表述，但本条公告本身不提供可提前交易的事实基础。
先例如何影响了这次决策
对本次决策的影响:先例不足不改变结论；核心原因是本条事件无新增基本面事实。
方向:例行投资者会议公告通常不提供可验证方向，本轮无需用低相似样本强行校准。
涨幅量级:没有可量化基本面增量，无法用先例校准涨跌幅。
形态:未形成可交易事件相位，不适用见光死或延续性判断。
原文全文
展开原文 · 1,742 字
CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) --
Beam Therapeutics Inc.
(Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:
Wells Fargo 21
st
Annual Healthcare Conference on Tuesday, September 8, 2026 at 1:30 p.m. ET in Boston
Citi’s Biopharma Back to School Conference on Wednesday, September 9, 2026 at 1:00 p.m. ET in New York
Cantor Fitzgerald Global Healthcare Conference 2026 on Thursday, September 10, 2026 at 8:00 a.m. ET in New York
The live webcasts will be available in the investor section of the company's website at
www.beamtx.com
and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contact:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
Beam Therapeutics Inc.
(Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:
Wells Fargo 21
st
Annual Healthcare Conference on Tuesday, September 8, 2026 at 1:30 p.m. ET in Boston
Citi’s Biopharma Back to School Conference on Wednesday, September 9, 2026 at 1:00 p.m. ET in New York
Cantor Fitzgerald Global Healthcare Conference 2026 on Thursday, September 10, 2026 at 8:00 a.m. ET in New York
The live webcasts will be available in the investor section of the company's website at
www.beamtx.com
and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contact:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。